Ignite Creation Date:
2024-06-16 @ 11:49 AM
Last Modification Date:
2024-10-26 @ 3:31 PM
Study NCT ID:
NCT06438679
Status:
ENROLLING_BY_INVITATION
Last Update Posted:
2024-06-03
First Post:
2024-05-13
Brief Title:
3T Therapy in the Treatment of MDA5-positive Dermatomyositis
Sponsor:
Second Affiliated Hospital School of Medicine Zhejiang University
Organization:
Second Affiliated Hospital School of Medicine Zhejiang University
Study Overview
Official Title:
A Single-centric Prospective Single-arm Study of 3T Therapy in the Treatment of MDA5-positive Dermatomyositis
Status:
ENROLLING_BY_INVITATION
Status Verified Date:
2024-02
Last Known Status:
None
Delayed Posting:
No
If Stopped, Why?:
Not Stopped
Has Expanded Access:
False
If Expanded Access, NCT#:
N/A
Has Expanded Access, NCT# Status:
N/A
Acronym:
None
Brief Summary:
The goal of this clinical trial is to learn if a combination of tacrolimus tafocitinib and thalidomide 3T therapy works to treat severe MDA5 positive dermatomyositis in adults It will also learn about the safety of 3T therapy The main questions it aims to answer are
Does 3T therapy prolong the overall survival time of MDA5 positive dermatomyositis What medical problems do participants have when taking 3T therapy
Participants will
Take 3T therapy every day for 12 months Visit the clinic once every 2 weeks for checkups and tests
Does 3T therapy prolong the overall survival time of MDA5 positive dermatomyositis What medical problems do participants have when taking 3T therapy
Participants will
Take 3T therapy every day for 12 months Visit the clinic once every 2 weeks for checkups and tests
Detailed Description:
None
Study Oversight
Has Oversight DMC:
None
Is a FDA Regulated Drug?:
False
Is a FDA Regulated Device?:
False
Is an Unapproved Device?:
None
Is a PPSD?:
None
Is a US Export?:
False
Is an FDA AA801 Violation?:
None